IMANIB

Active ingredient(s): imatinib mesilate

Consumer Medicine Information

This leaflet provides important information about using IMANIB. **You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using IMANIB.**

Where to find information in this leaflet:

1. Why am I using IMANIB?

2. What should I know before I use IMANIB?

3. What if I am taking other medicines?

4. How do I use IMANIB?

5. What should I know while using IMANIB?

6. Are there any side effects?

7. Product details

1. Why am I using IMANIB?

IMANIB contains the active ingredient imatinib. IMANIB belongs to a group of anti-cancer medicines known as tyrosine kinase inhibitors.

IMANIB is used to treat children and adults who have certain types of cancer and leukemia, including chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia with Philadelphia chromosome positive (Phpositive ALL).

IMANIB is also used to treat adults for:

Myelodysplastic / myeloproliferative diseases (MDS/ MPD).

These are a group of blood diseases in which some blood cells start growing out of control.

Aggressive systemic mastocytosis (ASM).

It is a cancer in which certain blood cells, called "mast" cells, grow out of control.

Hypereosinophilic syndrome (HES) and or chronic eosinophilic leukaemia (CEL).

These are blood diseases in which some blood cells, named "eosinophils", start growing out of control.

Gastro-intestinal stromal tumours (GIST).

This is a type of cancer of the stomach and bowels. This cancer affects the tissue that surrounds the stomach and bowels and the cells grow uncontrollably.

Dermatofibrosarcoma protuberans (DFSP).

DFSP is a cancer of the tissue beneath the skin in which some cells start growing out of control.

IMANIB works by slowing the growth of and killing cancer cells while leaving normal cells alone.

2. What should I know before I use IMANIB?

Warnings

Do not use IMANIB if:

- you are allergic to imatinib, or any of the ingredients listed at the end of this leaflet.